A pathogen reduction clinical trial in retrospect

Blood Transfusion

Volumn 15, Issue 4, 2017, Pages 329-332

  Rebulla, Paolo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APHERESIS; BLOOD COMPONENT; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); FUNDING; HEALTH PROGRAM; HUMAN; INTENTION TO TREAT ANALYSIS; NOTE; OUTCOME VARIABLE; PATHOGEN REDUCTION SYSTEM; PATIENT SELECTION; RECIPIENT; SAMPLE SIZE; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; BLOOD COMPONENT THERAPY; DISINFECTION; FEMALE; ITALY; MALE; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

BLOOD COMPONENT TRANSFUSION; DISINFECTION; FEMALE; HUMANS; ITALY; MALE; PRACTICE GUIDELINES AS TOPIC;

EID: 85021819927     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2017.0340-16     Document Type: Note

References (11)

1. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
2. Rebulla P, Vaglio S, Aprili G, et al. Clinical efficacy and safety of platelets in additive solution treated with two commercial pathogen reduction technologies. Transfusion 2015; 55: 3A-4A.
3. Ministero della Salute. Istituto Superiore di Sanità (ISS)-Progetti 2007. Available at: http://www.salute.gov.it/portale/temi/p2-6.jsp?lingua=italiano&id=1117&area=Ricerca%20 sanitaria&menu=finalizzata. Accessed on 29/11/2016.
4. Pharmaceutical Research and Manufacturers of America (PhRMA); Battelle Technology Partnership Practice. Biopharmaceutical industry-sponsored clinical trials: impact on state economies. Available at: http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf. Accessed on 29/11/2016.
5. Emanuel EJ, Schnipper LE, Kamin DY, et al. The costs of conducting clinical research. J Clin Oncol 2003; 21: 4145-50.
6. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380: 1309-16.
7. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013; 368: 1771-80.
8. Cook RJ, Heddle NM, Rebulla P, et al; Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society for Blood Transfusion. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion 2004; 44: 1135-42.
9. Cook RJ, Heddle NM. Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations. Transfusion 2013; 53: 1843-55.
10. Stanworth SJ, Hudson CL, Estcourt LJ, et al; TOPPS study investigators. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica 2015; 100: 740-7.
11. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: a2390.